Your browser doesn't support javascript.
loading
Amniocentesis in pregnancies at or beyond 24 weeks: an international multicenter study.
Zemet, Roni; Maktabi, Mohamad Ali; Tinfow, Alexandra; Giordano, Jessica L; Heisler, Thomas M; Yan, Qi; Plaschkes, Roni; Stokes, Jenny; Walsh, Jennifer M; Corcoran, Siobhán; Schindewolf, Erica; Miller, Kendra; Talati, Asha N; Miller, Kristen A; Blakemore, Karin; Swanson, Kate; Ramm, Jana; Bedei, Ivonne; Sparks, Teresa N; Jelin, Angie C; Vora, Neeta L; Gebb, Juliana S; Crosby, David A; Berkenstadt, Michal; Weisz, Boaz; Wapner, Ronald J; Van Den Veyver, Ignatia B.
Afiliación
  • Zemet R; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. Electronic address: roni.zemetlazar@bcm.edu.
  • Maktabi MA; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX.
  • Tinfow A; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
  • Giordano JL; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
  • Heisler TM; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
  • Yan Q; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
  • Plaschkes R; Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
  • Stokes J; Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
  • Walsh JM; Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
  • Corcoran S; Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
  • Schindewolf E; The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Miller K; The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Talati AN; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC.
  • Miller KA; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Blakemore K; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Swanson K; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA.
  • Ramm J; Department of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.
  • Bedei I; Department of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.
  • Sparks TN; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA.
  • Jelin AC; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Vora NL; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC.
  • Gebb JS; The Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Crosby DA; Department of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
  • Berkenstadt M; The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel.
  • Weisz B; Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
  • Wapner RJ; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
  • Van Den Veyver IB; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Division of Maternal-Fetal Medicine and Reproductive and Prenatal Genetics, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Fetal Center, Houston, TX. Electronic address: ive
Am J Obstet Gynecol ; 2024 Jun 22.
Article en En | MEDLINE | ID: mdl-38914189
ABSTRACT

BACKGROUND:

Amniocentesis for genetic diagnosis is most commonly done between 15 and 22 weeks of gestation but can be performed at later gestational ages. The safety and genetic diagnostic accuracy of amniocentesis have been well-established through numerous large-scale multicenter studies for procedures before 24 weeks, but comprehensive data on late amniocentesis remain sparse.

OBJECTIVE:

To evaluate the indications, diagnostic yield, safety, and maternal and fetal outcomes associated with amniocentesis performed at or beyond 24 weeks of gestation. STUDY

DESIGN:

We conducted an international multicenter retrospective cohort study examining pregnant individuals who underwent amniocentesis for prenatal diagnostic testing at gestational ages between 24w0d and 36w6d. The study, spanning from 2011 to 2022, involved 9 referral centers. We included singleton or twin pregnancies with documented outcomes, excluding cases where other invasive procedures were performed during pregnancy or if amniocentesis was conducted for obstetric indications. We analyzed indications for late amniocentesis, types of genetic tests performed, their results, and the diagnostic yield, along with pregnancy outcomes and postprocedure complications.

RESULTS:

Of the 752 pregnant individuals included in our study, late amniocentesis was primarily performed for the prenatal diagnosis of structural anomalies (91.6%), followed by suspected fetal infection (2.3%) and high-risk findings from cell-free DNA screening (1.9%). The median gestational age at the time of the procedure was 28w5d, and 98.3% of pregnant individuals received results of genetic testing before birth or pregnancy termination. The diagnostic yield was 22.9%, and a diagnosis was made 2.4 times more often for fetuses with anomalies in multiple organ systems (36.4%) compared to those with anomalies in a single organ system (15.3%). Additionally, the diagnostic yield varied depending on the specific organ system involved, with the highest yield for musculoskeletal anomalies (36.7%) and hydrops fetalis (36.4%) when a single organ system or entity was affected. The most prevalent genetic diagnoses were aneuploidies (46.8%), followed by copy number variants (26.3%) and monogenic disorders (22.2%). The median gestational age at delivery was 38w3d, with an average of 59 days between the procedure and delivery date. The overall complication rate within 2 weeks postprocedure was 1.2%. We found no significant difference in the rate of preterm delivery between pregnant individuals undergoing amniocentesis between 24 and 28 weeks and those between 28 and 32 weeks, reinforcing the procedure's safety across these gestational periods.

CONCLUSION:

Late amniocentesis, at or after 24 weeks of gestation, especially for pregnancies complicated by multiple congenital anomalies, has a high diagnostic yield and a low complication rate, underscoring its clinical utility. It provides pregnant individuals and their providers with a comprehensive diagnostic evaluation and results before delivery, enabling informed counseling and optimized perinatal and neonatal care planning.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Obstet Gynecol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Obstet Gynecol Año: 2024 Tipo del documento: Article
...